Key result
Personalized VV-ECMO anticoagulation balances high bleeding and thrombosis risks driven by disease and circuit interactions.
Why the study?
Bleeding and thrombotic complications occur regularly in VV-ECMO for severe ARDS, necessitating an assessment of coagulative state to facilitate a personalized approach to hemostasis.
A personalized approach to hemostasis is essential in VV-ECMO patients to manage bleeding and thrombotic complications.
May guide anticoagulation decisions in VV-ECMO; hypothesis-generating and warrants prospective validation before clinical adoption.
Venovenous extracorporeal membrane oxygenation (VV-ECMO) is a lifesaving therapy in severe acute respiratory distress syndrome (ARDS). Unfortunately, bleeding and thrombotic complications occur regularly due to coagulation disorders associated with the device, the underlying disease, and the anticoagulation management. To facilitate a personalized approach to hemostasis in individuals receiving ECMO support, it is essential to assess the coagulative state of the patient while simultaneously taking into account the underlying medical condition and administered therapies.
No takes yet. Share an insight, caveat, or question.
Jung et al. (2025) conducted a review in Severe acute respiratory distress syndrome (ARDS) requiring venovenous extracorporeal membrane oxygenation (VV-ECMO). Anticoagulation management was evaluated. A personalized approach to anticoagulation in VV-ECMO is essential to balance the high risks of bleeding and thrombosis, driven by underlying disease and extracorporeal circuit interactions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Frontiers in Medicine